Join ASH in our relentless pursuit of change, as we actively shape policies that impact the very heart of hematology research and practice. We empower researchers, clinicians, and patients through education, equipping lawmakers, and government officials with the knowledge they need to make a difference. Together, we unite our voice to revolutionize the future of hematology for the better.
ASH Advocacy's Latest Impact on Hematology
ASH and other members of the biomedical research and public health communities continue to strongly urge Congress to provide increased annual funding for NIH, CDC and other federal public health agencies and programs-increased resources are needed now more than ever.
Misconceptions about transfusions and limited funds hinder access to patients' end-of-life care. ASH prompts calls for innovative reimbursement models and increased support for palliative transfusions in hospice settings.
Since 2015, ASH has been committed to improving the outcomes for individuals living with SCD through collaborations with federal agencies, the U.S. Congress, and the U.S. Department of Health and Human Services.
High maternal mortality rates in the United States, with a particular disparity among non-Hispanic Black women, underscore the need to address hematologic complications in pregnancy. While advocating for diverse maternal perspectives and experiences, ASH stands that no woman should face legal ramifications for childbearing decisions.
Enhance Transfusion Care for Hospice Patients
The Improving Access to Transfusion Care for Hospice Patients Act (S. 2186) introduced in the U.S. Senate aims to enhance access to blood transfusions for end-of-life care patients under the Medicare hospice benefit by establishing a demonstration program for separate payment.
Cosponsor the SCDCCA
The SCDCCA aims to address the current issue where many individuals with SCD lack access to knowledgeable healthcare providers, striving to improve access to comprehensive, high-quality outpatient care for those affected.
Resolve Drug Shortages in Hematology and Oncology Care
Drug shortages are reaching an all-time high in hematology and oncology care. ASH continues to keep members apprised of shortages and work with Congress, federal agencies, and other stakeholders to ensure continued access to safe and effective hematologic drugs.
The ASH Congressional Fellowship is a year-long opportunity that allows an ASH member to work in a congressional office on Capitol Hill, Washington, DC, for an academic year to help shape health care and hematology policy.
ALI is a two-day workshop in Washington, DC where ASH members can gain a better understanding of the Society, learn about how Congress and health policy impact hematology research and practice, and meet with Members of Congress and their staff on Capitol Hill.
This Collaboration is a two-day workshop in Washington, DC, co-hosted by the U.S. Food and Drug Administration, for ASH members to network with FDA staff and learn about clinical and translational research, drug development, and regulatory medicine.